NASDAQ:INGN - Inogen Stock Price, Forecast & News

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen Inc (NASDAQ:INGN) announced its quarterly earnings data on Tuesday, November, 5th. The medical technology company reported $0.31 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.23 by $0.08. The medical technology company had revenue of $91.76 million for the quarter, compared to analysts' expectations of $91.65 million. Inogen had a net margin of 8.76% and a return on equity of 9.89%. The business's revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.73 earnings per share. View Inogen's Earnings History.

Inogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Inogen.

Inogen issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $361.4-362.4 million, compared to the consensus revenue estimate of $372.96 million.

7 analysts have issued 1-year price targets for Inogen's stock. Their forecasts range from $47.00 to $90.00. On average, they anticipate Inogen's share price to reach $65.00 in the next twelve months. This suggests a possible upside of 39.4% from the stock's current price. View Analyst Price Targets for Inogen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen.

Media stories about INGN stock have been trending positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Inogen earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Inogen.

Inogen saw a drop in short interest in the month of December. As of December 13th, there was short interest totalling 2,340,000 shares, a drop of 6.8% from the November 28th total of 2,510,000 shares. Based on an average daily trading volume, of 342,300 shares, the days-to-cover ratio is presently 6.8 days. Approximately 12.9% of the company's shares are short sold. View Inogen's Current Options Chain.

Some companies that are related to Inogen include Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC), Lakeland Industries (LAKE), ConforMIS (CFMS), Histogenics (HSGX), COLLPLANT HOLDI/S (CLGN), Rewalk Robotics (RWLK), NanoVibronix (NAOV), Allied Healthcare Products (AHPI), Ocugen (OCGN) and Precision Therapeutics (POAI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), First Solar (FSLR), Netflix (NFLX), Micron Technology (MU) and Paypal (PYPL).

Inogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.23%), Summit Creek Advisors LLC (0.66%), California Public Employees Retirement System (0.18%), New York State Teachers Retirement System (0.15%), Chicago Capital LLC (0.12%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Riverbridge Partners LLC, CWM Advisors LLC, Summit Creek Advisors LLC, Chicago Capital LLC, Curbstone Financial Management Corp, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. View Insider Buying and Selling for Inogen.

INGN stock was bought by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, California Public Employees Retirement System, SG Americas Securities LLC, TRUE Private Wealth Advisors and Magnus Financial Group LLC. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch and Loren L Mcfarland. View Insider Buying and Selling for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $46.64.

Inogen has a market capitalization of $1.03 billion and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen.

The official website for Inogen is http://www.inogen.com/.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]